2017
Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody–Positive Myasthenia Gravis
Robeson KR, Kumar A, Keung B, DiCapua DB, Grodinsky E, Patwa HS, Stathopoulos PA, Goldstein JM, O’Connor K, Nowak RJ. Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody–Positive Myasthenia Gravis. JAMA Neurology 2017, 74: 60-66. PMID: 27893014, DOI: 10.1001/jamaneurol.2016.4190.Peer-Reviewed Original ResearchConceptsDurability of responseMyasthenia gravisRituximab treatmentAnti-AChR antibody levelsB cell-targeted therapiesLong-term clinical responseRetrospective case series studyTreatment of MGEvidence-based practice parametersLast rituximab treatmentRefractory myasthenia gravisSerum cytokine levelsComplete stable remissionSubset of patientsCase series studyMyasthenia Gravis FoundationMG clinicPharmacologic remissionRituximab cyclesSustained remissionAutoantibody levelsInflammatory markersRituximab therapyClinical improvementClinical response
2015
A 15‐year‐old girl with a rapidly progressing tumor‐like lesion
Keung B, Huttner A. A 15‐year‐old girl with a rapidly progressing tumor‐like lesion. Neuropathology 2015, 35: 497-501. PMID: 26011248, DOI: 10.1111/neup.12207.Peer-Reviewed Original Research